Literature DB >> 24861246

Which imaging technique should we use in the follow up of gynaecological cancer?

Antonia Carla Testa1, Alessia Di Legge2, Bruna Virgilio1, Matteo Bonatti3, Riccardo Manfredi3, Paoletta Mirk4, Vittoria Rufini5.   

Abstract

Follow-up routines after gynaecological cancer vary. The optimal approach is unknown, and no randomised-controlled trials comparing surveillance protocols have been published. In this chapter, we summarise the diagnostic performance of ultrasound, computed tomography, and magnetic resonance imaging in the follow up of women treated for ovarian or uterine cancers. Computed tomography is today the standard imaging method for the follow up of women treated for endometrial, cervical, or ovarian cancer. Six-monthly or annual follow-up examinations have not been shown to positively affect survival. Instead, a combination of transvaginal and transabdominal ultrasound examination with clinical examination might be a more cost-effective strategy for early detection of recurrence. Positron-emission tomography might play a role in women with clinical or serological suspicion of recurrence but without evidence of disease at conventional diagnostic imaging. To create guidelines, more studies, preferably randomised-controlled trials, on follow-up strategies are needed.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  computed tomography; gynaecological cancer recurrences; imaging techniques; magnetic resonance imaging; positron emission tomography; ultrasound

Mesh:

Year:  2014        PMID: 24861246     DOI: 10.1016/j.bpobgyn.2014.04.008

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  2 in total

1.  Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.

Authors:  Elena Pereira; Olga Camacho-Vanegas; Sanya Anand; Robert Sebra; Sandra Catalina Camacho; Leopold Garnar-Wortzel; Navya Nair; Erin Moshier; Melissa Wooten; Andrew Uzilov; Rong Chen; Monica Prasad-Hayes; Konstantin Zakashansky; Ann Marie Beddoe; Eric Schadt; Peter Dottino; John A Martignetti
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

2.  Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma.

Authors:  Quan Quan; Qianqian Liao; Wanchun Yin; Shuwei Zhou; Sainan Gong; Xiaoling Mu
Journal:  Sci Rep       Date:  2021-11-04       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.